114 related articles for article (PubMed ID: 10520033)
1. Serum interleukin-6 has no discriminatory role in paraproteinaemia nor a prognostic role in multiple myeloma.
Schaar CG; Kaiser U; Snijder S; Ong F; Hermans J; Franck PF; Kluin-Nelemans JC
Br J Haematol; 1999 Oct; 107(1):132-8. PubMed ID: 10520033
[TBL] [Abstract][Full Text] [Related]
2. Soluble CD56 (NCAM): a new differential-diagnostic and prognostic marker in multiple myeloma.
Kaiser U; Oldenburg M; Jaques G; Auerbach B; Havemann K
Ann Hematol; 1996 Sep; 73(3):121-6. PubMed ID: 8841099
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of serum IL-6 level in monoclonal gammopathies.
DuVillard L; Guiguet M; Casasnovas RO; Caillot D; Monnier-Zeller V; Bernard A; Guy H; Solary E
Br J Haematol; 1995 Feb; 89(2):243-9. PubMed ID: 7873373
[TBL] [Abstract][Full Text] [Related]
4. Serum neural cell adhesion molecule differentiates multiple myeloma from paraproteinemias due to other causes.
Ong F; Kaiser U; Seelen PJ; Hermans J; Wijermans PW; de Kieviet W; Jaques G; Kluin-Nelemans JC
Blood; 1996 Jan; 87(2):712-6. PubMed ID: 8555495
[TBL] [Abstract][Full Text] [Related]
5. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY;
Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters.
Nachbaur DM; Herold M; Maneschg A; Huber H
Ann Hematol; 1991; 62(2-3):54-8. PubMed ID: 2031968
[TBL] [Abstract][Full Text] [Related]
7. Clinical features and outcome of multiple myeloma arising from the transformation of a monoclonal gammapathy of undetermined significance.
Patriarca F; Fanin R; Silvestri F; Candoni A; Zaja F; Sperotto A; Geromin A; Baccarani M
Leuk Lymphoma; 1999 Aug; 34(5-6):591-6. PubMed ID: 10492084
[TBL] [Abstract][Full Text] [Related]
8. Selection of patients with monoclonal gammopathy of undetermined significance is mandatory for a reliable use of interleukin-6 and other nonspecific multiple myeloma serum markers.
Greco C; Ameglio F; Alvino S; Cianciulli AM; Giovannelli M; Mattei F; Vitelli G; Venturo I; Lopez M; Gandolfo GM
Acta Haematol; 1994; 92(1):1-7. PubMed ID: 7985475
[TBL] [Abstract][Full Text] [Related]
9. Serum neural cell adhesion molecule in multiple myeloma and other plasma cell disorders.
Smith SR; Auerbach B; Morgan L
Br J Haematol; 1996 Jan; 92(1):67-70. PubMed ID: 8562413
[TBL] [Abstract][Full Text] [Related]
10. Management of paraproteinaemia.
Cook L; Macdonald DH
Postgrad Med J; 2007 Apr; 83(978):217-23. PubMed ID: 17403946
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of serum neural cell adhesion molecule as a prognostic marker in multiple myeloma.
Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):3021-4. PubMed ID: 9329591
[TBL] [Abstract][Full Text] [Related]
12. Soluble CD16 (sCD16), a marker of malignancy in individuals with monoclonal gammopathy of undetermined significance (MGUS).
Mathiot C; Mary JY; Tartour E; Facon T; Monconduit M; Grosbois B; Pollet JP; Michaux JL; Euller Ziegler L; Sautès C; Bataille R; Fridman WH
Br J Haematol; 1996 Dec; 95(4):660-5. PubMed ID: 8982042
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma.
Stasi R; Brunetti M; Parma A; Di Giulio C; Terzoli E; Pagano A
Cancer; 1998 May; 82(10):1860-6. PubMed ID: 9587117
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in multiple myeloma.
Kyle RA
Stem Cells; 1995 Aug; 13 Suppl 2():56-63. PubMed ID: 8520513
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma].
Scudla V; Budíková M; Petrová P; Minarík J; Pika T; Bacovský J; Adamová D; Langová K;
Klin Onkol; 2010; 23(3):171-81. PubMed ID: 20608327
[TBL] [Abstract][Full Text] [Related]
16. [The CBO professional guideline 'monoclonal gammopathy' (paraproteinemia) (revision)].
Buiting AM; Wijermans PW
Ned Tijdschr Geneeskd; 2002 Jul; 146(30):1406-11. PubMed ID: 12174434
[TBL] [Abstract][Full Text] [Related]
17. [Contribution to the evaluation of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and in individual clinical stages of multiple myeloma].
Scudla V; Petrová P; Minarík J; Pika T; Budíková M; Bacovský J; Repovský S
Vnitr Lek; 2010 Jun; 56(6):591-601. PubMed ID: 20681472
[TBL] [Abstract][Full Text] [Related]
18. [Determination of interleukin-6 messenger RNA as malignant progression index in monoclonal gammapathy of undetermined significance].
Mancini R; Palange M; Dionisi MG; De Angelis V; Matteocci A; Strano L
Recenti Prog Med; 1999 Oct; 90(10):522-6. PubMed ID: 10592737
[TBL] [Abstract][Full Text] [Related]
19. The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma.
Alexandrakis MG; Passam FH; Ganotakis ES; Sfiridaki K; Xilouri I; Perisinakis K; Kyriakou DS
Clin Lab Haematol; 2003 Feb; 25(1):41-6. PubMed ID: 12542441
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.
Bataille R; Jourdan M; Zhang XG; Klein B
J Clin Invest; 1989 Dec; 84(6):2008-11. PubMed ID: 2592570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
